C

Central Pharmaceutical JSC No3
VN:DP3

Watchlist Manager
Central Pharmaceutical JSC No3
VN:DP3
Watchlist
Price: 51 300 VND -0.19% Market Closed
Market Cap: 1.1T VND
Section:
 

Relative Value

The Relative Value of one DP3 stock under the Base Case scenario is 57 043.58 VND. Compared to the current market price of 51 300 VND, Central Pharmaceutical JSC No3 is Undervalued by 10%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

DP3 Relative Value
Base Case
57 043.58 VND
Undervaluation 10%
Relative Value
Price
C
Worst Case
Base Case
Best Case

Valuation Multiples

2.6
P/S
P/S
Price to Sales
2.6
vs History
61
vs Industry
38
Median 3Y
3.2
Median 5Y
2.9
Industry
2.6
Forward
2 498.9
More Details
8.5
P/E
P/E
Price to Earnings
8.5
vs History
77
vs Industry
38
Median 3Y
11.3
Median 5Y
10.2
Industry
21.7
Forward
7.7
More Details
9.9
P/OCF
P/OCF
Price to OCF
9.9
vs History
58
vs Industry
33
Median 3Y
11.7
Median 5Y
10.2
Industry
16.6
More Details
8.6
P/FCFE
P/FCFE
Price to FCFE
8.6
vs History
85
vs Industry
27
Median 3Y
13.8
Median 5Y
11.5
Industry
22.5
More Details
2.1
P/B
P/B
Price to Book Value
2.1
vs History
95
vs Industry
31
Median 3Y
3
Median 5Y
2.7
Industry
2.3
More Details
1.7
EV/S
EV/S
Enterprise Value to Sales
1.7
vs History
80
vs Industry
47
Median 3Y
2.6
Median 5Y
2.2
Industry
2.9
Forward
1 596.1
More Details
2.5
EV/GP
EV/GP
Enterprise Value to Gross Profit
2.5
vs History
80
vs Industry
57
Median 3Y
3.8
Median 5Y
3.2
Industry
5.5
More Details
4.3
EV/EBITDA
EV/EBITDA
Enterprise Value to EBITDA
4.3
vs History
88
vs Industry
42
Median 3Y
7.6
Median 5Y
6.9
Industry
13.1
More Details
4.9
EV/EBIT
EV/EBIT
Enterprise Value to EBIT
4.9
vs History
87
vs Industry
44
Median 3Y
7.9
Median 5Y
6.9
Industry
16.6
More Details
6.3
EV/OCF
EV/OCF
Enterprise Value to OCF
6.3
vs History
82
vs Industry
41
Median 3Y
9.3
Median 5Y
8.2
Industry
15.8
More Details
6.5
EV/FCFF
EV/FCFF
Enterprise Value to FCFF
6.5
vs History
93
vs Industry
33
Median 3Y
9.6
Median 5Y
9.9
Industry
19.1
More Details
2.7
EV/IC
EV/IC
Enterprise Value to IC
2.7
vs History
84
vs Industry
22
Median 3Y
4
Median 5Y
3.3
Industry
1.9
More Details

Multiples Across Competitors

DP3 Competitors Multiples
Central Pharmaceutical JSC No3 Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
VN
Central Pharmaceutical JSC No3
VN:DP3
1.1T VND 2.6 8.5 4.3 4.9
US
Eli Lilly and Co
NYSE:LLY
955.6B USD 16.1 51.9 34.9 37.4
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
US
Johnson & Johnson
NYSE:JNJ
485.9B USD 5.3 19.3 15.8 20.5
CH
Roche Holding AG
SIX:ROG
247.6B CHF 4 26.3 11.3 13.1
UK
AstraZeneca PLC
LSE:AZN
210.8B GBP 4.8 29.9 108.2 158.4
CH
Novartis AG
SIX:NOVN
205.5B CHF 4.6 17.7 11.3 14.6
US
Merck & Co Inc
NYSE:MRK
248B USD 3.9 13 9.3 11
DK
Novo Nordisk A/S
CSE:NOVO B
1.4T DKK 4.4 13.2 9.3 10.8
IE
Endo International PLC
LSE:0Y5F
202.5B USD 87.3 -69.3 321.2 805.4
US
Pfizer Inc
NYSE:PFE
148B USD 2.4 15.1 7.6 10.4
P/E Multiple
Earnings Growth PEG
VN
C
Central Pharmaceutical JSC No3
VN:DP3
Average P/E: 21.7
8.5
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
51.9
53%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A N/A
US
Johnson & Johnson
NYSE:JNJ
19.3
29%
0.7
CH
Roche Holding AG
SIX:ROG
26.3
29%
0.9
UK
AstraZeneca PLC
LSE:AZN
29.9
38%
0.8
CH
Novartis AG
SIX:NOVN
17.7
17%
1
US
Merck & Co Inc
NYSE:MRK
13
15%
0.9
DK
Novo Nordisk A/S
CSE:NOVO B
13.2
4%
3.3
IE
E
Endo International PLC
LSE:0Y5F
Negative Multiple: -69.3 N/A N/A
US
Pfizer Inc
NYSE:PFE
15.1
29%
0.5
EV/EBITDA Multiple
EBITDA Growth EV/EBITDA to Growth
VN
C
Central Pharmaceutical JSC No3
VN:DP3
Average EV/EBITDA: 398.1
4.3
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
34.9
33%
1.1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
3 846.3
36%
106.8
US
Johnson & Johnson
NYSE:JNJ
15.8
9%
1.8
CH
Roche Holding AG
SIX:ROG
11.3
4%
2.8
UK
AstraZeneca PLC
LSE:AZN
108.2
10%
10.8
CH
Novartis AG
SIX:NOVN
11.3
6%
1.9
US
Merck & Co Inc
NYSE:MRK
9.3
6%
1.5
DK
Novo Nordisk A/S
CSE:NOVO B
9.3
2%
4.6
IE
E
Endo International PLC
LSE:0Y5F
321.2
N/A N/A
US
Pfizer Inc
NYSE:PFE
7.6
1%
7.6
EV/EBIT Multiple
EBIT Growth EV/EBIT to Growth
VN
C
Central Pharmaceutical JSC No3
VN:DP3
Average EV/EBIT: 1 708.1
4.9
N/A N/A
US
Eli Lilly and Co
NYSE:LLY
37.4
36%
1
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
98%
180.6
US
Johnson & Johnson
NYSE:JNJ
20.5
15%
1.4
CH
Roche Holding AG
SIX:ROG
13.1
5%
2.6
UK
AstraZeneca PLC
LSE:AZN
158.4
23%
6.9
CH
Novartis AG
SIX:NOVN
14.6
12%
1.2
US
Merck & Co Inc
NYSE:MRK
11
8%
1.4
DK
Novo Nordisk A/S
CSE:NOVO B
10.8
1%
10.8
IE
E
Endo International PLC
LSE:0Y5F
805.4
N/A N/A
US
Pfizer Inc
NYSE:PFE
10.4
8%
1.3

See Also

Summary
DP3 intrinsic value, competitors valuation, and company profile.
DCF Valuation
DP3 stock valuation using Discount Cash Flow valuation method.
Relative Valuation
DP3 stock valuation using valuation multiples.
Wall Street Estimates
DP3 price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
DP3 stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
Back to Top
ALPHA SPREAD
Follow us
Join more than 301,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2025 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.